OR WAIT null SECS
CDMO HALIX will manufacture the drug substance for AstraZeneca’s COVID-19 vaccine candidate, AZD1222, at commercial scale at its cGMP facility in the Netherlands.
AstraZeneca announced on Dec. 8, 2020 that it has signed an agreement with HALIX, a biopharmaceutical contract development and manufacturing organization, for the large-scale commercial drug substance manufacturing of its vector-based COVID-19 vaccine, AZD1222.
Under the terms of the agreement, HALIX will handle the commercial manufacturing of the drug substance at its current good manufacturing practice (cGMP) facility at the Leiden Bio Science Park in the Netherlands, HALIX said in a company press release. HALIX will also continue its role as one of the original partners in the University of Oxford’s consortium for the manufacturing of the vaccine through the agreement.
“Building on the solid foundations made with the University of Oxford, it’s our pleasure to expand our manufacturing support of AZD1222 with AstraZeneca,” said Alex Huybens, chief operations officer, HALIX, in the press release. “Through the consortium, the partners are bringing their collective expertise and manufacturing capabilities to support vaccine production and combat this evolving crisis.”